TABLE 1.
Clinicopathologic characteristics of patients in the World IBC Consortium dataset whose data were used for our analysis (n = 314)
| No. (%) | ||||||
|---|---|---|---|---|---|---|
| Covariate | All n = 314 |
TNBC n = 84 |
HR+HER2− n = 173 |
HR−HER2+ n = 41 |
HR+HER2+ n = 16 |
P |
| Tumor | <0.0001 | |||||
| IBC | 86 (27.4) | 35 (40.7) | 26(30.2) | 20 (23.3) | 5 (5.8) | |
| Non-IBC | 228 (72.6) | 49 (21.5) | 147(64.5) | 21 (9.2) | 11 (4.8) | |
| Histologic characteristics | 0.1139 | |||||
| Ductal | 259 (82.5) | 76 (29.3) | 133 (51.4) | 37 (14.3) | 13 (5.0) | |
| Lobular | 26 (8.3) | 4 (15.4) | 20 (76.9) | 1 (3.8) | 1 (3.8) | |
| Others | 29 (9.2) | 4 (13.8) | 20 (69.0) | 3 (10.3) | 2 (6.9) | |
| Clinical stage | 0.0002 | |||||
| I | 65 (20.7) | 11 (16.9) | 48 (73.8) | 4 (6.2) | 2 (3.1) | |
| II | 97 (30.9) | 20 (20.6) | 63 (64.9) | 11 (11.3) | 3 (3.1) | |
| III | 152 (48.4) | 53 (34.9) | 62 (40.8) | 26 (17.1) | 11 (7.2) | |
| Lymphatic invasion | 0.1373 | |||||
| Unknown | 125 | |||||
| 0 | 108 (57.1) | 32 (29.6) | 58 (53.7) | 13 (12.0) | 5 (4.6) | |
| 1 | 81 (42.9) | 22 (27.2) | 34 (42.0) | 17 (21.0) | 8 (9.9) | |
| Genomic grade index | <0.0001 | |||||
| GR1 | 115 (36.6) | 15 (13.0) | 90 (78.3) | 6 (5.2) | 4 (3.5) | |
| GR3 | 199 (63.4) | 69 (34.7) | 83 (41.7) | 35 (17.6) | 12 (6.0) | |
| Nuclear grade | <0.0001 | |||||
| Unknown | 4 | |||||
| 1 | 50 (16.1) | 4 (8.0) | 46 (92.0) | 0 (0.0) | 0 (0.0) | |
| 2 | 106 (34.2) | 20 (18.9) | 74 (69.8) | 6 (5.7) | 6 (5.7) | |
| 3 | 154 (49.7) | 58 (37.7) | 51 (33.1) | 35 (22.7) | 10 (6.5) | |
| Neoadjuvant chemotherapy | 0.0001 | |||||
| Unknown | 11 | |||||
| No | 96 (31.7) | 24 (25.0) | 66 (68.8) | 2 (2.1) | 4 (4.2) | |
| Yes | 207 (68.3) | 59 (28.5) | 100 (48.3) | 37 (17.9) | 11 (5.3) | |
| Hormone treatment | <0.0001 | |||||
| Unknown | 78 | |||||
| No | 111 (47.0) | 45 (40.5) | 44 (39.6) | 20 (18.0) | 2 (1.8) | |
| Yes | 125 (53.0) | 14 (11.2) | 97 (77.6) | 6 (4.8) | 8 (6.4) | |
NOTE: P values reflect comparisons of covariate levels among the subgroups.
Abbreviations: HER2, human growth factor receptor 2; IBC, inflammatory breast cancer; HR, hormone receptor (estrogen receptor or progesterone receptor); TNBC, triple-negative breast cancer.